Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-Analysis - PubMed
7 hours ago
- #SGLT2 inhibitors
- #systematic review
- #older adults
- SGLT2 inhibitors (SGLT2i) in older adults reduce risks of acute renal failure (OR 0.86), mortality (OR 0.84), and serious adverse events (OR 0.84).
- SGLT2i increase risks of genital infections (OR 3.32) and volume depletion (OR 1.18), with genital infection risk higher at higher doses and escalating sharply with age (≥75 years OR 9.29).
- Mortality benefit is strongest in adults ≥75 years (OR 0.58), and intra-class analysis shows varying safety profiles among specific SGLT2i medications.
- Study uses a network meta-analysis of 97 trials, with moderate certainty evidence, confirming robustness through bootstrap and trial sequential analyses.
- Provides actionable insights for personalized therapy in geriatric care, highlighting a favorable benefit-risk profile despite certain risks requiring vigilance.